A look at how drug developers fare after floating in Europe suggests why many tread a path to the US and a Nasdaq listing.
Notable progress with antibody-drug conjugates from Seattle Genetics and Immunomedics drove the biggest Esmo share price moves.
Though late-breakers rightfully seize much of the limelight at the Esmo congress, investors should look further afield too.
Curevac’s market cap has ballooned almost fivefold since floating, sending the mRNA company into the record books.
All the attention is on aducanumab, but yesterday’s deal with Denali is a reminder that Biogen has other irons in the fire.
Shortly after canning its lead and acquiring the NK cell company Cytosen, Kiadis flips part of the tech to Sanofi.
But a 24% remission rate is still enough to get the project before the US regulator, analysts reckon.
Followers of Nordic Nanovector and Oxford Biomedica, among others, will pay close attention to an early focus of yesterday’s deal.